Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.JPMorgan Chase: The target price of Netflix was raised from $850 to $1,010, and the "overweight" rating was maintained.Wang Honghai, former chairman of the Financial and Economic Committee of Tianjin Municipal People's Congress, was "double-opened" for illegal intervention and intervention in judicial activities. Recently, with the approval of the Tianjin Municipal Committee of the Communist Party of China, the Supervision Committee of Tianjin Municipal Commission for Discipline Inspection filed a case review and investigation on Wang Honghai, former member of the Standing Committee of the Municipal People's Congress, former chairman of the Financial and Economic Committee of the Municipal People's Congress and former director of the Budget Working Committee of the Standing Committee of the Municipal People's Congress. After investigation, Wang Honghai lost his ideals and beliefs, abandoned his initial mission, resisted organizational censorship, and personally engaged in superstitious activities; Ignoring the spirit of the eight central regulations, repeatedly accepting gifts and gifts in violation of regulations, arranging family members to accept tourism activities that may affect the fair execution of official duties, and borrowing vehicles for management services for a long time without compensation; Violation of organizational principles, using authority to seek benefits for others in the promotion and adjustment of cadres' positions; Violation of regulations and intervention in judicial activities, improper performance of duties in the work, resulting in adverse effects; Taking public power as a tool for personal gain, taking advantage of his position to make profits for others in project contracting and job transfer, and illegally accepting huge amounts of property.
On the 13th, silver fell by 1.91%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract silver was 2,502, up or down by -1.91%, with a turnover of 1,004,900 lots. The position data showed that the top 20 seats were net, and the difference position was 30,444 lots. The total turnover of silver futures contracts was 1,505,900 lots, an increase of 417,500 lots over the previous day. The first 20 seats in the contract held 335,600 lots, a decrease of 15,200 lots from the previous day. The short positions in the top 20 seats of the contract were 251,300 lots, an increase of 17,500 lots over the previous day. (Sina Futures)Shengyi Technology: The total sales volume of the company's rigid copper clad laminate ranks second in the world. Shengyi Technology said at the collective exchange meeting of investors that according to the statistics and ranking of the global rigid copper clad laminate in 2023 by Prismark of the United States, the total sales volume of the company's rigid copper clad laminate ranks second in the world, with a global market share of 14%. Regarding the growth trend of AI server, the company said that the upgrade iteration of hardware equipment related to AI server is fast, and the product form is quite different from that of previous wired products. The company can quickly respond to customer requirements and provide solutions. It is expected that AI applications will gradually develop from large model training to application in the future, and it is expected to achieve good growth.Wen Ning Ke, former CEO of ASML, will be the chairman of the supervisory board of Heineken in April next year. Heineken Holdings announced on December 13th that Peter Wen Ning Ke, vice chairman of the supervisory board and former CEO of ASML, will be the chairman of the supervisory board in April next year, replacing Jean-Marc Huët. Wen Ning Ke joined the Board of Supervisors of Heineken at this year's annual general meeting of shareholders, and is an important member of the Audit Committee, Remuneration Committee and Selection and Appointment Committee.
Vegetable oil fell by 1.90% on the 13th, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract vegetable oil closed at 2,505, up or down by -1.90%, with a turnover of 535,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 21,545 lots. The total turnover of vegetable oil futures contracts was 593,700 lots, a decrease of 112,100 lots from the previous day. The first 20 seats in the contract held 232,900 lots, a decrease of 3,819 lots from the previous day. The short positions in the top 20 seats of the contract were 254,200 lots, an increase of 687 lots over the previous day. (Sina Futures)To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)Report: By 2035, the demand for hydrogen in the global power industry may increase fourfold. According to analysis, the demand for clean hydrogen in the global power industry will reach 4 million tons by 2035. This is five times the scale of 800,000 tons of clean hydrogen agreements signed by the power industry at present. The power industry is increasingly interested in hydrogen, which is good news for hydrogen producers who are competing to find an off-buyer. However, from the climate point of view, the prospect is not so optimistic, because most global reserve projects plan to burn hydrogen and natural gas together.
Strategy guide
12-14
Strategy guide
Strategy guide 12-14
Strategy guide 12-14